Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;152(3):R63-78.
doi: 10.1530/REP-16-0052. Epub 2016 May 10.

Endometriosis: where are we and where are we going?

Affiliations
Review

Endometriosis: where are we and where are we going?

Alexis D Greene et al. Reproduction. 2016 Sep.

Abstract

Endometriosis currently affects ~5.5 million reproductive-aged women in the U.S. with symptoms such as painful periods (dysmenorrhea), chronic pelvic pain, pain with intercourse (dyspareunia), and infertility. It is defined as the presence of endometrial tissue outside the uterine cavity and is found predominately attached to sites within the peritoneal cavity. Diagnosis for endometriosis is solely made through surgery as no consistent biomarkers for disease diagnosis exist. There is no cure for endometriosis and treatments only target symptoms and not the underlying mechanism(s) of disease. The nature of individual predisposing factors or inherent defects in the endometrium, immune system, and/or peritoneal cavity of women with endometriosis remains unclear. The literature over the last 5 years (2010-2015) has advanced our critical knowledge related to hormones, hormone receptors, immune dysregulation, hormonal treatments, and the transformation of endometriosis to ovarian cancer. In this review, we cover the aforementioned topics with the goal of providing the reader an overview and related references for further study to highlight the progress made in endometriosis research, while concluding with critical areas of endometriosis research that are urgently needed.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest: ADG, SAL, JAK, JMS-R, and KAB do not have any conflict of interests to disclose. TJH, in the last two years, has served on Advisory boards to: Roche/Genentech, AstraZeneca, Caris Life Sciences, Clovis Oncology, and Johnson & Johnson.

References

    1. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67:817–821. - PubMed
    1. Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health. 2014;6:671–680. - PMC - PubMed
    1. Acien P, Velasco I, Acien M, Capello C, Vela P. Epithelial ovarian cancers and endometriosis. Gynecol Obstet Invest. 2015;79:126–135. - PubMed
    1. Agarwal S, Fraser MA, Chen I, Singh SS. Dienogest for the treatment of deep endometriosis: case report and literature review. J Obstet Gynaecol Res. 2015;41:309–313. - PubMed
    1. Ahn S, Monsanto S, Miller C, Singh S, Thomas R, Tayade C. Pathophysiology and Immune Dysfunction in Endometriosis. Biomed Res Int. 2015a;2015:795976. - PMC - PubMed

Publication types